REGENXBIO Inc. RGNX · Stock Open REGENXBIO Inc. in new tab
REGENXBIO Inc. Analysis (RGNX)
Is REGENXBIO Inc. a good investment? REGENXBIO Inc. (RGNX) is currently trading at 9.96 USD. Market analysts have a consensus price target of 24.27 USD. This suggests a potential upside from current levels.
Earnings Schedule: REGENXBIO Inc. is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -2.54.
Investor FAQ
Does REGENXBIO Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is REGENXBIO Inc.?
REGENXBIO Inc. is classified as a Stock. You can compare it against 6 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -5.60.
Company Profile
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Community Discussion